Literature DB >> 12269846

The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications.

Toomas Podar1, Jaakko Tuomilehto.   

Abstract

Evidence suggests that ACE inhibitors can be advantageous for prevention and halting progression of both micro- and macrovascular complications in patients with diabetes mellitus. ACE inhibitors are useful antihypertensive agents in both type 1 and type 2 diabetes; however, ACE inhibitor therapy often needs to be supplemented with calcium channel antagonists, beta-blockers or diuretics to achieve good blood pressure control. ACE inhibitors are also indicated in non-hypertensive patients with type 1 and type 2 diabetes who have micro- or macroalbuminuria. The effect of ACE inhibitors in halting the development and progression of retinopathy and, potentially, neuropathy needs further proof in large-scale studies. More recently, angiotensin II receptor antagonists are emerging as drugs with the potential to be successfully included in the management of diabetic complications, especially when ACE inhibitors are not suitable because of adverse effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12269846     DOI: 10.2165/00003495-200262140-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  38 in total

Review 1.  Role of angiotensin II in diabetic nephropathy.

Authors:  D J Leehey; A K Singh; N Alavi; R Singh
Journal:  Kidney Int Suppl       Date:  2000-09       Impact factor: 10.545

2.  The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.

Authors:  L Golan; J D Birkmeyer; H G Welch
Journal:  Ann Intern Med       Date:  1999-11-02       Impact factor: 25.391

3.  Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project.

Authors:  L Niskanen; T Hedner; L Hansson; J Lanke; A Niklason
Journal:  Diabetes Care       Date:  2001-12       Impact factor: 19.112

4.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

6.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Authors:  C E Mogensen; S Neldam; I Tikkanen; S Oren; R Viskoper; R W Watts; M E Cooper
Journal:  BMJ       Date:  2000-12-09

7.  Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus.

Authors:  N Chaturvedi; A K Sjolie; J M Stephenson; H Abrahamian; M Keipes; A Castellarin; Z Rogulja-Pepeonik; J H Fuller
Journal:  Lancet       Date:  1998-01-03       Impact factor: 79.321

8.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

Review 9.  National High Blood Pressure Education Program Working Group report on hypertension in diabetes.

Authors: 
Journal:  Hypertension       Date:  1994-02       Impact factor: 10.190

10.  Is ACE inhibition with lisinopril helpful in diabetic neuropathy?

Authors:  A Reja; S Tesfaye; N D Harris; J D Ward
Journal:  Diabet Med       Date:  1995-04       Impact factor: 4.359

View more
  4 in total

Review 1.  End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function.

Authors:  Giuliano Tocci; Massimo Volpe
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

Review 2.  Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.

Authors:  André J Scheen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  The crosstalk among TLR2, TLR4 and pathogenic pathways; a treasure trove for treatment of diabetic neuropathy.

Authors:  Seyed Hossein Aghamiri; Khalil Komlakh; Mehran Ghaffari
Journal:  Inflammopharmacology       Date:  2022-01-12       Impact factor: 4.473

Review 4.  Diabetic neuropathy: mechanisms to management.

Authors:  James L Edwards; Andrea M Vincent; Hsinlin T Cheng; Eva L Feldman
Journal:  Pharmacol Ther       Date:  2008-06-13       Impact factor: 12.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.